Impedimed
- Short interest
- <0.01%
- −0.33 pp 30d
- as of 2 July 2026
- Reported shorts
- 99.8K
- Shares on issue
- 3.660B
Impedimed (IPD) financials
Results, ratios and statements
Latest result
Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency
- Revenue
- $14.6Mvs $12.7M (FY25)
- Yahoo Finance, as at 29 Oct 2026
- NPAT
- −$24.9Mvs −$23.2M (FY25)
- Yahoo Finance, as at 29 Oct 2026
- EPS (diluted)
- −$0.012vs −$0.011 (FY25)
- Yahoo Finance, as at 29 Oct 2026
- Rev YoY
- +14.8%FY
- EPS YoY
- n/aFY
Summary of 2026 Annual Report, 27 Aug 2026
ImpediMed's FY26 revenue rose 15% to $14.6 million, with net profit not disclosed. No dividend was declared. The company highlighted expanded reimbursement coverage for breast cancer-related lymphoedema to 95% of the U.S. population and a strengthened balance sheet via a $15.3 million capital raise, targeting cash flow breakeven.
Automated summary of the filing; the filing itself is the record.
Key ratios
Year to 30 Jun 2026 (FY); balance sheet at 30 Jun 2026; prices to 30 Oct 2026
- Gross margin
- 87.4%
- Operating margin
- −153.7%
- Net margin
- −170.4%
- FCF margin
- −130.9%
- ROE
- −162.4%
- ROA
- −65.3%
- FCF conversion
- n/a
- Net debt (excl. leases)
- $801.0K
- Net debt / EBITDA
- n/a
- Current ratio
- 3.8×
- Interest cover
- −5.2×
- Cash dividends paid / net profit
- n/a
- Market cap
- $14.6M
- P/E
- n/a
- P/B
- 1.4×
Ratios use the reporting currency (AUD); market cap is in AUD. Source: Yahoo Finance, as at 29 Oct 2026.
Financial statements
Figures in AUD, the reporting currency; Yahoo Finance unless marked
| Line item | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | $14.6M | $12.7M | $10.1M | $11.2M |
| Gross profit | $12.8M | $11.0M | $8.7M | $9.7M |
| Operating income | −$22.5M | −$24.2M | −$24.3M | −$23.0M |
| EBITDA | −$16.3M | −$17.6M | −$22.1M | −$20.5M |
| EBIT | −$20.5M | −$22.1M | −$24.3M | −$23.0M |
| Interest expense | $4.4M | $1.1M | n/a | n/a |
| Pretax income | −$24.9M | −$23.2M | −$19.8M | −$20.5M |
| Tax | $26.0K | $26.0K | $33.0K | $31.0K |
| NPAT | −$24.9M | −$23.2M | −$19.8M | −$20.5M |
| Net interest income | −$3.6M | −$204.0K | $1.5M | $767.0K |
| EPS basic | −$0.012 | −$0.011 | −$0.010 | −$0.011 |
| EPS diluted | −$0.012 | −$0.011 | −$0.010 | −$0.011 |
| Shares | 3.66B | 2.03B | 2.02B | 2.02B |
Financial reports
The company's own filings, newest first
- Quarterly Activities Report and Appendix 4C - Sep-2026 QtrQuarterly Report30 Oct 2026via asx_announcements
- 2026 Annual ReportAnnual Report27 Aug 2026via asx_announcements
- Appendix 4EAnnual Results27 Aug 2026via asx_announcements
- Quarterly Activities Report and Appendix 4C - Jun-2026 QtrQuarterly Report28 Jul 2026via asx_announcements
- Quarterly Activities Report and Appendix 4C - Mar-2026 QtrQuarterly Report30 Apr 2026via asx_announcements
- FY26 Half Year Financial ResultsHalf Year Results26 Feb 2026via asx_announcements
- Appendix 4D and Interim Financial ReportHalf Year Results26 Feb 2026via asx_announcements
- Quarterly Activities Report and Appendix 4C - Dec-2025Quarterly Report29 Jan 2026via asx_announcements
- DF50Financial Report31 Dec 2025via crawler
- L-Dex® U400Financial Report31 Dec 2025via crawler
Showing 10 of 109 reports